AperçuGraphiqueTechniqueActualités
Dérivés
TraderScreen

Cellectis SA/  FR0010425595  /

Euronext - Paris
08/11/2024  17:35:22 Chg. +0.022 Volume Bid17:40:00 Demandez à17:40:00 Haut Bas
1.710EUR +1.30% 20,226
Chiffrre d'affaires: 34,218.274		 1.674Bid taille: 153 1.718Ask la taille: 33 1.714 1.672
GlobeNewswire 26/08 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Rec...
GlobeNewswire 08/08 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First...
GlobeNewswire 07/08 Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
GlobeNewswire 07/08 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
GlobeNewswire 06/08 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 01/08 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswire 25/07 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product c...
GlobeNewswire 16/07 Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as D...
GlobeNewswire 01/07 Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase ...
GlobeNewswire 28/06 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswire 20/06 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswire 20/06 Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cem...
GlobeNewswire 12/06 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswire 04/06 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...
GlobeNewswire 29/05 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
GlobeNewswire 28/05 Cellectis Reports Financial Results for First Quarter 2024
GlobeNewswire 27/05 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
GlobeNewswire 13/05 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire 09/05 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire 06/05 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 02/05 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
GlobeNewswire 29/04 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
GlobeNewswire 26/04 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire 22/04 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...
GlobeNewswire 10/04 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...